Short answer
Amylyx Pharmaceuticals, Inc. (AMLX) filed its fiscal 2025 10-K annual report with the SEC on Mar 3, 2026. It reported revenue of $0 (−100.0% year over year) and net income of −$145M.
- Top risk flagged: Cybersecurity risk oversight by board and executive team with escalation for material incidents to audit committee
FY2025 key financial metrics · XBRL
- Revenue
- $0
- −100.0% YoY
- Net income
- −$145M
- +52.0% YoY
- EPS (diluted)
- −$1.53
- +65.5% YoY
- ROE
- -47.4%
- +135.7 pp YoY
- Operating cash flow
- −$123M
- +26.4% YoY
Source: XBRL data from the Amylyx Pharmaceuticals, Inc. (AMLX) FY2025 10-K on SEC EDGAR. USD.
Amylyx Pharmaceuticals, Inc. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: Clinical-stage pharma developing novel therapies for endocrine and neurodegenerative diseases with mechanistic rationale and biomarker-driven pipeline
- New products: Advanced Phase 3 trial for avexitide in PBH; initiated Phase 1 trial for AMX0114 in ALS and selected AMX0318 for long-acting GLP-1 antagonist development
- Strategic shift: Acquired avexitide patent portfolio in July 2024, expanding IP estate significantly; emphasis on broader rare disease indications including Wolfram syndrome and ALS
- Quantitative metric: Patent estate grew to 23 U.S. and 257 foreign issued patents plus 130+ pending applications as of Dec 31, 2025; 75 participants enrolled in Phase 3 LUCIDITY trial
- Noteworthy fact: Positive Phase 2 HELIOS data for AMX0035 in Wolfram syndrome showing sustained pancreatic beta cell function improvement through 48 weeks
Management Discussion & Analysis
- Revenue $0 in 2025 vs $87.4M in 2024, 100% decline due to discontinuation of RELYVRIO®/ALBRIOZA™ product sales
- Operating loss $153.3M in 2025 vs $314.7M in 2024, a 51% improvement; R&D expenses down 13% to $90.4M; SG&A down 45% to $62.9M
- Best performing segment: Avexitide R&D up 771% to $24.1M; worst: AMX0035-ALS R&D down 95% to $1.8M
- Cash from financing $257.0M in 2025 led by two equity offerings raising approx. $256.2M net; operating cash burn $123.3M; cash & equivalents $317.0M at year-end
- Management expects R&D and G&A expenses to increase as clinical programs advance; key risks include clinical trial outcomes, regulatory approvals, and capital access
Risk Factors
- Cybersecurity risk oversight by board and executive team with escalation for material incidents to audit committee
- Dependence on Senior Director of ISGA with CISSP and 20+ years experience for daily information security strategy
- Reliance on external vendors for managed network support and security operations creating supply chain cybersecurity risk
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.